Vasgen Limited to Participate in the Japan–Drug Discovery and Development Event 25/02/2013 -01/03/2013
Vasgen Limited (“Vasgen” or “the Company”), a new speciality biotech company, is to participate in the Japan-Drug Discovery and Development Event organised by the UKTI /Scottish Development International.
Offering a unique opportunity to network with Japan’s biotech, pharmaceutical and life science investor communities, Dr Salman Rahman CEO and co-founder of Vasgen said: “Japan boasts the world’s second largest pharmaceutical market and has more than 30 million people over the age of 65, a demographic that aligns with Vasgen’s therapeutic focus on age-dependent ocular neovascular diseases and cancer. This event is a great opportunity for even an early stage company such as ours to raise its profile in the Asia pacific market.”
-Ends-
Notes to Editors
Vasgen limited is a new London-based biotech company developing innovative ocular and cancer therapeutics to meet unmet clinical needs. The Company’s technologies include AbIMPTM, a novel antibody-based approach allowing development of highly selective inhibitors of metalloproteinase catalytic activity with a particular focus on the ADAMs gene family of sheddases. The Company’s lead product under development is a pre-clinical stage therapeutic AbIMP targeting ADAM15 for anti-angiogenesis therapy. More information is available at www.vasgen.co.uk